Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

41.53
-0.8300-1.96%
Post-market: 41.530.00000.00%19:55 EDT
Volume:1.76M
Turnover:73.64M
Market Cap:10.79B
PE:14.94
High:42.70
Open:42.36
Low:41.49
Close:42.36
52wk High:49.62
52wk Low:32.38
Shares:259.71M
Float Shares:223.00M
Volume Ratio:0.57
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):2.78
ROE:35.53%
ROA:19.27%
PB:4.99
PE(LYR):14.94

Loading ...

Exelixis Earnings Call: CABOMETYX Strength, ZANZA Catalyst

TIPRANKS
·
Feb 12

Exelixis Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 11

RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating

MT Newswires Live
·
Feb 11

GUIDANCE: (EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B - $2.63B, vs. FactSet Est of $2.62B

MT Newswires Live
·
Feb 11

Exelixis Q4 Non-GAAP Earnings, Revenue Rise

MT Newswires Live
·
Feb 11

Oncology company Exelixis Q4 revenue slightly misses estimates

Reuters
·
Feb 11

Exelixis posts FY 2025 non-GAAP net income of USD 869.5 million

Reuters
·
Feb 11

BRIEF-Exelixis Q4 Revenue USD 599 Million Vs. IBES Estimate USD 604.2 Million

Reuters
·
Feb 11

Exelixis Outlook FY Revenue USD 2,525-2,625 Million

THOMSON REUTERS
·
Feb 11

Exelixis Q4 Adjusted EPS USD 0.94 VS. Ibes Estimate USD 0.79

THOMSON REUTERS
·
Feb 11

Exelixis Inc - Gaap Diluted EPS of $0.88 for Q4 of 2025

THOMSON REUTERS
·
Feb 11

Exelixis Q4 Revenue USD 599 Million VS. Ibes Estimate USD 604.2 Million

THOMSON REUTERS
·
Feb 11

Exelixis Inc - Maintains Financial Guidance for FY 2026

THOMSON REUTERS
·
Feb 11

Press Release: Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Feb 11

U.S. Earnings Preview: After Market Close Feb. 10

Dow Jones
·
Feb 11

U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday

Reuters
·
Feb 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 09

FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test

Simply Wall St.
·
Feb 07

Exelixis Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Feb 04

Barclays Sticks to Its Hold Rating for Exelixis (EXEL)

TIPRANKS
·
Feb 04